NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/05/2026
Back to search
Official data from USPTO
HONGENE BIOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
05/05/2026
Classification
Registered
Trademark type
Combined
Nice classes
1, 5
Filing date
05/10/2024
Registration date
05/05/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/05/2026
Last transaction
05/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/22/2024
First use in commerce
04/22/2024
Drawing code
3
Owner type
03
Owner location
Shanghai, CN
Examiner
SOBRAL, CHRISTINA
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized stacked words HONGENE BIOTECH to the left of which is a triangular shape comprised of the letters HG.
Holders and representatives
Holders
S. C. (pessoa física)
Representatives
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
adjuvantsother than for medical or veterinary purposes; bases in the nature of alkalies being chemical preparations; biochemical catalysts; biological preparations for use in industry and scienceother than for medical or veterinary purposes; carbonic hydrates; biochemical catalysts; chemical preparations for scientific purposesother than for medical or veterinary use; chemical reagentsother than for medical or veterinary purposes; chemical substances for analyses in laboratoriesother than for medical or veterinary purposes; chemical preparations for analyses in laboratoriesother than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparationsother than for medical or veterinary purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; ferments for chemical purposesfermentation extract; glucose for industrial purposesglucosides; industrial chemicals; isotopes for industrial purposes preparations of microorganismsother than for medical and veterinary use; salts being chemical preparations; sulfides
Class 5
biological preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease for medical purposes; biological preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease for veterinary purposes; capsules sold empty for medicines; chemical preparations for medical purposes for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease; chemical preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease for pharmaceutical purposes; chemical preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease for veterinary purposes; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; drugs being pharmaceutical preparations for treatment and prevention of ocular diseasecerebral diseasecentral nervous system diseasecardiovascular disease and metabolic disease for medical purposes; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; ferments for pharmaceutical purposes; immunostimulants; isotopes for medical purposes; medical preparations for slimming purposes; medicinal hair growth preparations; medicines for treatment and prevention of cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss for human purposes; medicines for veterinary purposes for treatment and prevention of cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss; pharmaceutical preparations for treatment and prevention cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss; pharmaceuticals for treatment and prevention of cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss; phosphates for pharmaceutical purposes for treatment and prevention of cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss; preparations of microorganisms for medical or veterinary use; vaccines; veterinary preparations for treatment and prevention of cancerHIVhepatitis Ahepatitis Binfluenzameaslesneurodegenerative diseasestransthyretin (TTR)-mediated amyloidosis (ATTR)hemophiliaporphyriacomplement-mediated diseasehypercholesterolemiarare genetic diseasescardio-metabolic diseaseshepatic infectious diseaseshereditary ATTR amyloidosisrare bleeding disordershepatic porphyriasalpha-1 antitrypsin deficiencyprimary hyperoxaluria type 1beta-thalassemiairon overload disordershereditary angiodemahypertriglyceridemiamixed hyperlipidemiahypertriglyceridemiahypertensionpreeclampsiathromboprophylaxishepatitis B virus infectionhepatitis D virus infectionchronic liver infectionobesityhair loss
Publications
History of USPTO decisions and trademark events.
25 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/05/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/15/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/15/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/14/2026
IUAF
USE AMENDMENT FILED
11/06/2025
EISU
TEAS STATEMENT OF USE RECEIVED
11/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/13/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/13/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/13/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/11/2025
PUBO
PUBLISHED FOR OPPOSITION
03/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/14/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/13/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/25/2024
GNRT
NON-FINAL ACTION E-MAILED
11/25/2024
CNRT
NON-FINAL ACTION WRITTEN
11/25/2024
DOCK
ASSIGNED TO EXAMINER
11/25/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/10/2024
NWAP
NEW APPLICATION ENTERED
05/10/2024
Continuous trademark protection
Get notified about every new filing that threatens HONGENE BIOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.